自愿披露关于2026年度经营业绩预测的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百济神州有限公司（以下简称"公司"）于 2026 年 2 月 26 日发布根据美 国公认会计原则及美国证券交易委员会适用规则编制的截至 2025 年 12 月 31 日 止年度经审计财务业绩并同步发布根据中国企业会计准则编制的 2025 年度未经 审计业绩快报公告。为让投资者更好地了解公司经营业绩情况和未来业绩前景， 公司将 2026 年度经营业绩预测情况公告如下： 一、2026 年度经营业绩预测 综合近年来的业务发展趋势，公司预计的中国企业会计准则下 2026 年全年 的经营业绩如下： | | 年度经营业绩预测 2026 | | | | --- | --- | --- | --- | | 营业收入 | 将介于人民币 436 450 | 亿元至 | 亿元之间 | | 毛利率% | 80%区间的高位 | | | | 研发费用、销售及管理费用合计 | 将介于人民币 333 | 亿元至 348 | 亿元之间 | A 股代码：688235 ...

北京商报讯（记者 丁宁）2月26日晚间，百济神州（688235）发布关于2026年度经营业绩预测的公告显 示，综合近年来的业务发展趋势，公司预计的中国企业会计准则下2026年营业收入将介于436亿元至450 亿元之间，毛利率将为80%区间的高位。 ...

Core Viewpoint - BeiGene reported a significant turnaround in its financial performance for the year 2025, achieving a total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit attributable to shareholders of 1.422 billion yuan, compared to a net loss of 4.978 billion yuan in the previous year [1] Financial Performance - The total revenue for 2025 reached 38.205 billion yuan, marking a 40.4% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the prior year [1] - The increase in revenue was primarily driven by sales growth of Baiyueze®, licensed products from Amgen, and Baizean® [1] Operational Efficiency - The company achieved profitability in operating profit, total profit, net profit attributable to shareholders, net profit excluding non-recurring items, and basic earnings per share compared to the previous year [1] - The improvement in profitability was attributed to revenue growth from products and enhanced operational efficiency driven by effective cost management [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司2025年度業績快 報公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2026年2月26日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執 行董事王曉東博士，以及獨立非執行董事 Olivier Brandicourt 博士、 Margaret Han Dugan博士、Michael Goller先生、Anthony C. Hooper先生、 Ranjeev Krishana先生、Alessandro Riva博士、Corazon (Cor ...

Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] Group 1: Financial Performance - The net profit attributable to the parent company was 1.422 billion yuan for the reporting period [1] - Total assets increased to 57.423 billion yuan, reflecting a growth of 34.1% compared to the beginning of the period [1] - Equity attributable to the parent company rose to 30.601 billion yuan, marking a 26.6% increase from the start of the period [1] Group 2: Product Performance - The global sales of Baiyueze reached 28.067 billion yuan, representing a year-on-year growth of 48.8%, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, up 45.5%, while European sales were 4.265 billion yuan, increasing by 66.4% [2] - In China, sales totaled 2.472 billion yuan, reflecting a growth of 33.1% [2] - Baiyueze's sales in 2025 were significantly driven by its broad regulatory approvals and strong clinical efficacy data in chronic lymphocytic leukemia (CLL) [2] Group 3: Clinical Development - Baiyueze is the only BTK inhibitor with flexible dosing options and has been involved in over 45 clinical trials across more than 30 countries, enrolling over 7,900 patients [3] - The drug has shown significant benefits in progression-free survival (PFS) in the global Phase 3 ALPINE trial, with a median follow-up of 29.6 months [3] - The company plans to conduct a mid-term analysis of the Phase 3 MANGROVE trial in the first half of 2026 [3] Group 4: Other Products - Baizean, a cornerstone product for solid tumors, has shown potential across various cancer types and has been approved in over 50 markets globally [4] - The company is expanding Baizean's market presence and has reported significant survival improvements in HER2-positive gastric cancer patients when combined with chemotherapy [4] - Regulatory submissions for new indications of Baizean are expected in the first half of 2026 in the U.S. and China [4]

Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, while total assets increased by 34.1% to 57.423 billion yuan, and equity attributable to the parent company rose by 26.6% to 30.601 billion yuan [1] Product Performance - The global sales of Baiyueze® reached 28.067 billion yuan, marking a 48.8% year-on-year growth, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, a 45.5% increase, while European sales were 4.265 billion yuan, up 66.4%, and sales in China totaled 2.472 billion yuan, increasing by 33.1% [2] - Bai Ze An® achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth, and sales from Amgen's licensed products reached 3.471 billion yuan, up 33.6% [2] Clinical Development and Regulatory Approvals - Baiyueze® is the most widely approved BTK inhibitor globally, with over 45 clinical trials conducted across more than 30 countries, enrolling over 7,900 patients [3] - The drug has received regulatory approvals in over 75 markets and demonstrated significant benefits in progression-free survival (PFS) in clinical trials, reinforcing its status as a preferred BTK inhibitor [3] - Bai Ze An® has shown potential across various tumor types, with clinical trials involving over 15,800 participants in more than 33 countries, and has been approved in over 50 markets [4] - The company plans to submit new indications for Bai Ze An® in the U.S. and China in the first half of 2026, with expectations for regulatory decisions in Japan by the second half of 2026 [4]

Core Insights - The company reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.40% [1] - The net profit attributable to shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the same period last year [1] - The basic earnings per share stood at 1 yuan [1] Revenue Breakdown - Product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year [1] - The growth in product revenue was primarily driven by sales of Baiyueze® (Zebutinib), licensed products from Amgen, and Baizean® (Tislelizumab) [1]

A 股代码：688235 A 股简称：百济神州 公告编号：2026-002 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司披露 的经审计后的 2025 年年度报告为准，提请投资者注意投资风险。 本公告财务数据按中国企业会计准则编制并呈列。 本公司已于 2026 年 2 月 26 日同步发布了根据美国公认会计原则及美国证券 交易委员会适用规则编制的截至 2025 年 12 月 31 日止年度经审计财务业绩，提请投 资者注意与本公告区别。 1 一、2025 年度主要财务数据和指标 单位：人民币千元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 38,204,601 | 27,213, ...

格隆汇2月26日丨百济神州(688235.SH)公布，预计2026年营业收入将介于人民币436亿元至450亿元之 间，毛利率约为80%区间的高位，营业收入扣除经调整的经营成本费用将介于人民币98亿元至105亿元 之间。 ...

Financial Performance - In Q4 2025, the company reported total global revenue of $1.5 billion, a year-on-year increase of 33% [1] - For the full year 2025, total global revenue reached $5.3 billion, reflecting a 40% year-on-year growth [1] - Adjusted net profit for Q4 2025 was approximately $225 million, a significant increase of 1,297% year-on-year [1] - The full year adjusted net profit for 2025 was about $918 million, marking a return to profitability [1] - Free cash flow for Q4 2025 was $380 million, an increase of $397 million compared to the same period last year [1] - For the full year 2025, free cash flow totaled $942 million, an increase of $1.6 billion year-on-year [1] - The revenue guidance for the full year 2026 is projected to be between $6.2 billion and $6.4 billion [1] Product Performance - The global sales of Baiyueze (Zebutinib) in Q4 2025 reached $1.1 billion, a 38% year-on-year increase [1] - The annual global sales of Baiyueze for 2025 were $3.9 billion, representing a 49% growth compared to the previous year [1] - Global sales of Baizean (Trelatuzumab) in Q4 2025 were $18.2 million, an 18% increase year-on-year [1] - The total annual sales of Baizean for 2025 were $73.7 million, reflecting a 19% year-on-year growth [1] Strategic Insights - The strong financial performance in Q4 2025 and for the full year underscores the company's evolution as a leader in the global oncology treatment sector [2] - The company has established a durable competitive advantage in clinical development and production, supported by a differentiated R&D pipeline [2] - Baiyueze has solidified its position as a global leader in the BTK inhibitor space, with extensive regulatory approvals and strong clinical recognition [2] - The company is expanding the indications and reimbursement coverage for Baizean in major global markets [2] - With several cornerstone hematologic oncology products nearing commercialization and promising data from solid tumor pipelines, the company aims for sustainable global growth [2]